The Global Deterioration Scale for assessment of primary degenerative dementia

1982/09/01 by ‌Barry Reisberg, Steven H. Ferris, Mony J. de Leon +1 · 41 citations
Economics, Econometrics and Finance · Medicine · #Health Systems, Economic Evaluations, Quality of Life #Dementia and Cognitive Impairment Research #Frailty in Older Adults

paper · doi:10.1176/ajp.139.9.1136

Abstract

Cognitive decline associated with old age and consistent with the diagnosis of primary degenerative dementia is a unique clinical syndrome with characteristic phenomena and progression. The authors describe a Global Deterioration Scale for the assessment of primary degenerative dementia and delineation of its stages. The authors have used the Global Deterioration Scale successfully for more than 5 years and have validated it against behavioral, neuroanatomic, and neurophysiologic measures in patients with primary degenerative dementia.

Cited by

• Hippocampal Atrophy in Normal Aging
• Prediction of Dementia by Subjective Memory Impairment<subtitle>Effects of Severity and Temporal Association With Cognitive Impairment</subtitle><alt-title>Dementia and Subjective Memory Impairment</alt-title>
• Mild Cognitive Impairment
• Depression in Patients With Mild Cognitive Impairment Increases the Risk of Developing Dementia of Alzheimer Type
• Determination of cadmium and zinc in Alzheimer's brain tissue using Inductively Coupled Plasma Mass Spectrometry
• Turn-taking and speech act patterns in the discourse of senile dementia of the Alzheimer's type patients
• Prevalence of dementia in adult patients with trisomy 21
• Progressive age-related impairment of cognitive behavior in APP23 transgenic mice
• Working memory and control of attention in persons with Alzheimer's disease and mild cognitive impairment.
• Assessment of the severely impaired patient: Description and validation of a new neuropsychological test battery.
• Fragmentation of activity periods in Alzheimer's disease
• How do care-related beliefs contribute to depression and anxiety in family caregivers of people with dementia? Testing a cognitive vulnerability-stress model
• The COMFORTage project: study protocol for the integration of multiple sources towards personalised preventions at Ace Alzheimer Center Barcelona
• Erythrocyte membrane characteristics indicate abnormal cellular aging in patients with Alzheimer's disease
• Processing Faces in Alzheimer’s Disease Patients: How a Familiar Face Becomes Unfamiliar
• The Impact of APOE ε4 on Neuropsychological Test Performance in Hispanics: The Panama Aging Research Initiative – Health Disparities Study
• Hippocampal hypometabolism predicts cognitive decline from normal aging. [europepmc]
• Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. [europepmc]
• FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. [europepmc]
• The clinical course of advanced dementia. [europepmc]
• Outcome over seven years of healthy adults with and without subjective cognitive impairment. [europepmc]
• The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. [europepmc]
• Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. [europepmc]
• Cerebral blood flow in Alzheimer's disease. [europepmc]
• The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. [europepmc]
• Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. [europepmc]
• A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. [europepmc]
• Periodontal disease associates with higher brain amyloid load in normal elderly. [europepmc]
• Early neurone loss in Alzheimer's disease: cortical or subcortical? [europepmc]
• Association Between Oral Health and Cognitive Status: A Systematic Review. [europepmc]
• Effect of the Goals of Care Intervention for Advanced Dementia: A Randomized Clinical Trial. [europepmc]
• The economic burden of dementia in China, 1990-2030: implications for health policy. [europepmc]
• Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer's disease. [europepmc]
• Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. [europepmc]
• NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. [europepmc]
• Alzheimer's Disease - Why We Need Early Diagnosis. [europepmc]
• The characterisation of subjective cognitive decline. [europepmc]
• Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. [europepmc]
• Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. [europepmc]
• Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. [europepmc]
• Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. [europepmc]

Related

• A New Clinical Scale for the Staging of Dementia
• Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores
• The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects
• A physical model for dementia
• Measuring disease progression in frontotemporal lobar degeneration